Adding Tafasitamab to Lenalidomide and Rituximab Prolongs PFS in Patients with Relapsed or Refractory Follicular Lymphoma By Ogkologos - December 18, 2025 355 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the inMIND study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment... April 3, 2025 Neoadjuvant Niraparib Demonstrates Promising Antitumour Activity and Safety in Patients with... August 10, 2022 For People with Cancer, Are Steroids the Best Treatment for Breathing... October 25, 2022 FDA Approves Pembrolizumab as Adjuvant Treatment for NSCLC February 2, 2023 Load more HOT NEWS Toothbrushes and ctDNA: Exciting early detection concepts from new teams formed... FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations Neoadjuvant Nivolumab/Relatlimab Induces High Rates of Pathologic Responses in Patients with...
